Musa Tariq Sells 116 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of Guardant Health stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $130.19, for a total value of $15,102.04. Following the transaction, the director owned 8,796 shares of the company’s stock, valued at $1,145,151.24. This trade represents a 1.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $95.96, for a total value of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total value of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The stock was sold at an average price of $88.09, for a total value of $30,655.32.

Guardant Health Stock Up 1.4%

Guardant Health stock opened at $129.11 on Thursday. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $135.00. The company’s 50 day moving average price is $105.69 and its two-hundred day moving average price is $102.51. The stock has a market cap of $17.12 billion, a P/E ratio of -38.09 and a beta of 1.61.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC bought a new stake in Guardant Health during the 4th quarter valued at $35,000. Finally, Parallel Advisors LLC raised its holdings in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on GH. Citigroup lifted their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Piper Sandler set a $127.00 target price on shares of Guardant Health in a research report on Thursday, May 21st. Mizuho lifted their target price on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Finally, Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.